Lesson plan
IPALT
iPALT, or ALiPT, also known as N-isopropyl-N-allyltryptamine or by its developmental code name ASR-3003, is a serotonin receptor modulator of the tryptamine family. It is an asymmetrical analogue of diisopropyltryptamine (DiPT) and diallyltryptamine (DALT). The drug is a non-selective serotonin receptor agonist, including of the serotonin 5-HT 1B , 5-HT 2A , 5-HT 2B , and 5-HT 6 receptors, but not of the serotonin 5-HT 1A receptor. It is also a serotonin reuptake inhibitor, but does not inhibit dopamine or norepinephrine reuptake. The drug shows rather low potency for many of these actions, with for example 47-fold lower potency as a serotonin 5-HT 2A receptor agonist than the known psychedelic drug 5-MeO-iPALT (ASR-3001). The chemical synthesis of iPALT has been described. Derivatives of iPALT include 5-MeO-iPALT (ASR-3001), 4-HO-iPALT, and 2-Me-iPALT (ASR-3002). 5-MeO-iPALT is known to be a psychedelic drug in humans and is under development for potential medical use. iPALT was patented by the Alexander Shulgin Research Institute (ASRI) in 2024.
Article summary
iPALT, or ALiPT, also known as N-isopropyl-N-allyltryptamine or by its developmental code name ASR-3003, is a serotonin receptor modulator of the tryptamine family. It is an asymmetrical analogue of diisopropyltryptamine (DiPT) and diallyltryptamine (DALT). The drug is a non-selective serotonin receptor agonist, including of the serotonin 5-HT 1B , 5-HT 2A , 5-HT 2B , and 5-HT 6 receptors, but not of the serotonin 5-HT 1A receptor. It is also a serotonin reuptake inhibitor, but does not inhibit dopamine or norepinephrine reuptake. The drug shows rather low potency for many of these actions, with for example 47-fold lower potency as a serotonin 5-HT 2A receptor agonist than the known psychedelic drug 5-MeO-iPALT (ASR-3001). The chemical synthesis of iPALT has been described. Derivatives of iPALT include 5-MeO-iPALT (ASR-3001), 4-HO-iPALT, and 2-Me-iPALT (ASR-3002). 5-MeO-iPALT is known to be a psychedelic drug in humans and is under development for potential medical use. iPALT was patented by the Alexander Shulgin Research Institute (ASRI) in 2024.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.